Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Naunyn Schmiedebergs Arch Pharmacol
2023 Nov 01;39611:3149-3161. doi: 10.1007/s00210-023-02521-6.
Show Gene links
Show Anatomy links
Inhibitory effects of N-methyl-D-aspartate (NMDA) and α1-adrenergic receptor antagonist ifenprodil on human Kv1.5 channel.
Hwang S
,
Yoon B
,
Jo SH
.
???displayArticle.abstract???
Ifenprodil has been known to reduce cardiac contractility and cerebral vasodilation by antagonizing α1-adrenergic and N-methyl D-aspartate receptor-mediated intracellular signals. This study aimed to investigate the direct effect of ifenprodil on the human voltage-gated Kv1.5 channel (hKv1.5) by using a Xenopus oocyte expression system and a two-microelectrode voltage clamp technique. The amplitudes of hKv1.5 currents, including peak and steady state, were suppressed in a concentration-dependent manner (IC50; 43.1 and 35.5 μM, respectively) after 6 min of ifenprodil treatment. However, these effects were ~ 80% reversed by washout, suggesting that ifenprodil directly inhibited the hKv1.5 independent of membrane receptors or intracellular signals. The inhibition rate of steady state showed voltage dependence, wherein the rates increased according to test voltage depolarization. Ifenprodil reduced the time constants of hKv1.5 inactivation but has higher effects on activation. hKv1.5 inhibition by ifenprodil showed use dependency because the drug more rapidly reduced the current at the higher activation frequencies, and subsequent reduction in frequency after high activation frequency caused a partial channel block relief. Therefore, ifenprodil directly blocked the hKv1.5 in an open state and accelerated the time course of the channel inactivation, which provided a biophysical mechanism for the hKv1.5 blocking effects of ifenprodil.
Aydar,
The sigma receptor as a ligand-regulated auxiliary potassium channel subunit.
2002, Pubmed,
Xenbase
Aydar,
The sigma receptor as a ligand-regulated auxiliary potassium channel subunit.
2002,
Pubmed
,
Xenbase
Bath,
The effects of ifenprodil and eliprodil on voltage-dependent Ca2+ channels and in gerbil global cerebral ischaemia.
1996,
Pubmed
Bettahi,
Contribution of the Kir3.1 subunit to the muscarinic-gated atrial potassium channel IKACh.
2002,
Pubmed
Brittain,
Ifenprodil, a NR2B-selective antagonist of NMDA receptor, inhibits reverse Na+/Ca2+ exchanger in neurons.
2012,
Pubmed
Brunner,
In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype.
2003,
Pubmed
Chenard,
Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.
1991,
Pubmed
Choi,
Direct block by bisindolylmaleimide of rat Kv1.5 expressed in Chinese hamster ovary cells.
2000,
Pubmed
Christ,
Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation.
2008,
Pubmed
Christophersen,
Genetic variation in KCNA5: impact on the atrial-specific potassium current IKur in patients with lone atrial fibrillation.
2013,
Pubmed
Church,
Blockade by ifenprodil of high voltage-activated Ca2+ channels in rat and mouse cultured hippocampal pyramidal neurones: comparison with N-methyl-D-aspartate receptor antagonist actions.
1994,
Pubmed
Colatsky,
Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias.
1990,
Pubmed
Delpón,
Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels.
1997,
Pubmed
Doupnik,
The inward rectifier potassium channel family.
1995,
Pubmed
Ehrlich,
Atrial-selective approaches for the treatment of atrial fibrillation.
2008,
Pubmed
Fedida,
Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current.
1993,
Pubmed
Ford,
New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value.
2008,
Pubmed
Ford,
Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor.
2013,
Pubmed
Ford,
The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation.
2016,
Pubmed
Guo,
Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity.
2016,
Pubmed
Gutman,
International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels.
2005,
Pubmed
Hashimoto,
Further characterization of [3H]ifenprodil binding to sigma receptors in rat brain.
1993,
Pubmed
Hashimoto,
Interactions of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of sigma receptors.
1995,
Pubmed
Hashimoto,
Further characterization of [3H]ifenprodil binding in rat brain.
1994,
Pubmed
Hautz,
Targeting the Kv1.3 potassium channel for immunosuppression in vascularized composite allotransplantation - a pilot study.
2013,
Pubmed
Hayashi,
Functional Characterization of Rare Variants Implicated in Susceptibility to Lone Atrial Fibrillation.
2015,
Pubmed
Jo,
Protriptyline block of the human ether-à-go-go-related gene (HERG) K+ channel.
2008,
Pubmed
,
Xenbase
Karbon,
Ifenprodil potently interacts with [3H](+)-3-PPP-labeled sigma binding sites in guinea pig brain membranes.
1990,
Pubmed
Kidd,
Angiotensin II reduces the surface abundance of KV 1.5 channels in arterial myocytes to stimulate vasoconstriction.
2017,
Pubmed
Kobayashi,
Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil.
2006,
Pubmed
,
Xenbase
Kotecha,
A Kv1.5 to Kv1.3 switch in endogenous hippocampal microglia and a role in proliferation.
1999,
Pubmed
Krapivinsky,
The G-protein-gated atrial K+ channel IKACh is a heteromultimer of two inwardly rectifying K(+)-channel proteins.
1995,
Pubmed
,
Xenbase
Lee,
Open channel block of Kv1.5 currents by citalopram.
2010,
Pubmed
Lip,
Management of atrial fibrillation.
2007,
Pubmed
Loose,
Effects of IKur blocker MK-0448 on human right atrial action potentials from patients in sinus rhythm and in permanent atrial fibrillation.
2014,
Pubmed
McCool,
Ifenprodil inhibition of the 5-hydroxytryptamine3 receptor.
1995,
Pubmed
Monassier,
Sigma receptors: from discovery to highlights of their implications in the cardiovascular system.
2002,
Pubmed
Monassier,
Prevention by NMDA receptor antagonists of the centrally-evoked increases of cardiac inotropic responses in rabbits.
1994,
Pubmed
Monassier,
Effects of ifenprodil and baclofen on exercise-induced increase of myocardial oxygen demand in normotensive rats.
1999,
Pubmed
Monassier,
Effects of centrally-acting glutamatergic modulators on cardiovascular responses to stress in humans.
2001,
Pubmed
Monassier,
sigma(2)-receptor ligand-mediated inhibition of inwardly rectifying K(+) channels in the heart.
2007,
Pubmed
Novakova,
Highly selective sigma receptor ligands elevate inositol 1,4,5-trisphosphate production in rat cardiac myocytes.
1998,
Pubmed
Ohanyan,
Requisite Role of Kv1.5 Channels in Coronary Metabolic Dilation.
2015,
Pubmed
Olson,
Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation.
2006,
Pubmed
Pratt,
Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?
1998,
Pubmed
Reimann,
Inwardly rectifying potassium channels.
1999,
Pubmed
Ru,
Voltage-gated and ATP-sensitive K+ channels are associated with cell proliferation and tumorigenesis of human glioma.
2014,
Pubmed
Seo,
Asenapine, an atypical antipsychotic, blocks voltage-gated potassium channels in rabbit coronary artery smooth muscle cells.
2022,
Pubmed
Suessbrich,
The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes.
1997,
Pubmed
,
Xenbase
Sung,
Open channel block of Kv3.1 currents by fluoxetine.
2008,
Pubmed
Swanson,
Cloning and expression of cDNA and genomic clones encoding three delayed rectifier potassium channels in rat brain.
1990,
Pubmed
,
Xenbase
Walfridsson,
Is the acetylcholine-regulated inwardly rectifying potassium current a viable antiarrhythmic target? Translational discrepancies of AZD2927 and A7071 in dogs and humans.
2015,
Pubmed
Wang,
Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents.
1993,
Pubmed
Wettwer,
Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation.
2004,
Pubmed
Williams,
Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action.
2001,
Pubmed
Wulff,
The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.
2003,
Pubmed
Wulff,
Voltage-gated potassium channels as therapeutic targets.
2009,
Pubmed
Young,
Direct vascular effects of agents used in the pharmacotherapy of cerebrovascular disease on isolated cerebral vessels.
1981,
Pubmed
Young,
Cerebro-circulatory effects of so-called 'vasodilators' in the anaesthetised rat.
1983,
Pubmed
